|
An Update on the Pharmacological Treatments of COVID-19
|
|
| Author:
|
MAYSAA ALI ABDUL KHALEQ, SAAD RASOOL SHAKER, DILSHAD JALAL MOHAMMED, ALI MOHAMMED ABDULKAREEM, NAJAH R.HADI
|
| Abstract:
|
Researchers have tried many therapeutic agents in their experimental studies since the first pandemic time of COVID-19; these studies have been virus-based or host-based. Major therapeutics agent’s regimens evaluated in this review. Antiviral agents such as remdesivir, and Umifenovir should be used before the viral peak of replication to obtain the best clinical outcome. Dexamethasone is FDA approved in the treatment of certain cases of Covid-19. Immunoglobulin, and Interferon effectiveness in the treatment of this pandemic disease is not clear due to inconsistent outcomes data obtained in many studies. Several studies that used chloroquine and hydroxychloroquine as a therapeutic agent in COVID-19 showed that these agents have in vitro inhibitory activity against SARS-CoV-2, but failed to show a significant effect in many clinical studies. For patients who develop cytokine storm the interleukine-6 inhibitors like Tocilizumab could be effective.
|
| Keyword:
|
COVID-19, Pharmacological Treatments of COVID-19
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.03.470
|
| Download:
|
Request For Article
|
|
|